Navigation Links
Conseco Reports Third Quarter Results
Date:10/31/2007

expenses 1,262.0 1,041.6 3,622.2 3,181.2

Income (loss) before

income taxes (86.8) 76.7 (163.3) 142.9

Income tax expense

(benefit) on

period income (33.1) 28.3 (60.1) 52.2

Net income (loss) (53.7) 48.4 (103.2) 90.7

Preferred stock

dividends - 9.5 14.1 28.5

Net income (loss)

applicable to

common stock $ (53.7) $ 38.9 $ (117.3) $ 62.2

Earnings per common

share:

Basic:

Weighted average

shares outstanding 187,733,000 151,663,000 169,270,000 151,566,000

Net income (loss) $ (.29) $ .26 $ (.69) $ .41

Diluted:

Weighted average

shares outstanding 187,733,000 152,529,000 169,270,000 152,547,000

Net income (loss) $ (.29) $ .26 $ (.69) $ .41

CONSECO, INC. AND SUBSIDIARIES

OPERATING RESULTS

Results by segment for the nine months ended September 30 were as follows ($ in millions):

Nine Months Ended

September 30,

2007 2006

EBIT (2), excluding costs related to a

litigation settlement and loss related

to a coinsurance transaction:

Bankers Life $ 174.6 $ 189.3

Conseco Insurance Group 101.4 173.9

Colonial Penn 18.3 16.2

Other Business in Run-off (167.0) 15.4

Corporate Operations, excludin
'/>"/>

SOURCE Conseco, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Though the number of jobs created i... companies reported a different kind of slowdown: ...s months. , Seattle, WA (...created in the medical field slowed in June overal...ind of slowdown that will be music to the ears of ...
(Date:7/25/2008)... supporting the US Department of Defense and Feder... Phoenix. Operation Golden Phoenix is a, four-da...ned to assist, federal, state and local agencies w...os. Dataline is providing a vital, ad-hoc, secure ... use during the exercise., NORFOLK, Va., July 25 ...
(Date:7/25/2008)...elationship Based on Significant Improvements in M...MDdatacor, Inc., a leader in health,care quality m..., today,announced it has entered into a long-term ...rt Wellmark,s Collaboration on Quality(SM) Incent ...ion between Wellmark and,primary care clinicians t...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...ldren can be treated effectively with a single dos...ajor global health problem particularly in // chil...resource-limited countries where cholera occurs, a...tant as it reduces the demands on the healthcare s...
... effective in prevent the brain damages similar to...th Florida have found that a component of green te...ns of mice genetically programmed to develop the n... component, called epigallocatechin-3-gallate (EGC...
...t smoking is injurious to health. The maximum harm...cts of smoking may be understood by the effect it ...xidase A (MAOA) is important in mood regulation an... regulate blood pressure. In a new study, research...
...hange the curriculum for medicine by integrating m...ment it within two years. "Today's medical curric...ation of both the modern and traditional practices... to come out within two years time," said health m...
Other Medicine News:
(Date:7/24/2008)...gned to take body temperature, for home,and clinic...ll/ --- Kidz-Med, Inc.,(subsidiary of American Sci...States distributor of the Thermofocus(R) 5-in-1 no...results of a clinical study,conducted by the Secon...,Milan, Italy, which proves that the Thermofocus(R...
(Date:7/23/2008)...-- Sound Pharmaceuticals (SPI) has filed,an Invest...e clinical,testing of a proprietary formulation of...d hearing loss or ototoxicity. The oral capsule,co...nced stage lung cancer,and head and neck cancer pa... marks the second development program for SPI to e...
(Date:7/23/2008)...irstCall/ -- Dendreon Corporation,(Nasdaq: DNDN )...ata,Monitoring Committee (IDMC) to review in Octob...elating to the Company,s Phase 3 IMPACT (IMmunothe...nown as D9902B) clinical trial,of PROVENGE(R) (sip...nal,active cellular immunotherapy for the treatmen...
(Date:7/22/2008)...cs Development Initiative bring MJFF,s,current act...anuary 20,2009, NEW YORK, July 22 /PRNewswire-US...ery of transformative treatments and a cure for Pa...or Parkinson,s Research has awarded,$2.7 million i...e awards,were granted under MJFF,s Therapeutics De...
Breaking Medicine Technology:Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 1Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 2Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 3DNC 3A Rudy Shows Again Hes Out of Touch With Americas Priorities 8922 1DNC 3A Rudy Shows Again Hes Out of Touch With Americas Priorities 8922 2DNC 3A Rudy Shows Again Hes Out of Touch With Americas Priorities 8922 3Risk of HIV West Nile Virus E Coli Transmission May be Reduced Through Improved Blood Screening Methods 8918 1Risk of HIV West Nile Virus E Coli Transmission May be Reduced Through Improved Blood Screening Methods 8918 2Holiday Travel Bad Eating Habits a Recipe for Stomach Trouble 8916 1Holiday Travel Bad Eating Habits a Recipe for Stomach Trouble 8916 2
...RIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - Comb...ed the presentation of,additional data related to ...2 and CRx-139, at the European League Against,Rheu...ting, June,13-16, 2007 in Barcelona, Spain., CRx-1...e and Chondrocyte,Inflammatory Mediators by CRx-10...
...FORD, Conn.--(BUSINESS WIRE)--Jun 13, 2007 - Neuro...t data from previous,Phase 1 and Phase 2a clinical...or the treatment of insomnia, were presented in tw... Associated,Professional Sleep Societies (APSS) in...dies with NG2-73 in chronic insomnia patients,are ...
Other Medicine Technology:Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 4Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 5
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: